Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Gains from Investment Securities (2016 - 2025)

Ironwood Pharmaceuticals' Gains from Investment Securities history spans 17 years, with the latest figure at $3.4 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities changed N/A year-over-year to $3.4 million; the TTM value through Dec 2025 reached $3.4 million, up 361.21%, while the annual FY2025 figure was $3.4 million, 25.13% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was $3.4 million at Ironwood Pharmaceuticals, up from -$7000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $10.0 million in Q4 2023 and bottomed at -$10.7 million in Q4 2021.
  • The 5-year median for Gains from Investment Securities is -$18000.0 (2021), against an average of $222864.9.
  • The largest annual shift saw Gains from Investment Securities tumbled 2352.94% in 2022 before it soared 3342.11% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at -$10.7 million in 2021, then skyrocketed by 110.61% to $1.1 million in 2022, then soared by 779.44% to $10.0 million in 2023, then plummeted by 91.9% to $807000.0 in 2024, then skyrocketed by 321.2% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Gains from Investment Securities are $3.4 million (Q4 2025), -$7000.0 (Q3 2025), and $807000.0 (Q3 2024).